AUPH vs. IGMS, CYRX, YMAB, AMRN, KROS, XENE, CORT, FOLD, IDYA, and PTCT
Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include IGM Biosciences (IGMS), Cryoport (CYRX), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), Keros Therapeutics (KROS), Xenon Pharmaceuticals (XENE), Corcept Therapeutics (CORT), Amicus Therapeutics (FOLD), IDEAYA Biosciences (IDYA), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical preparations" industry.
Aurinia Pharmaceuticals (NASDAQ:AUPH) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership.
Aurinia Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.
In the previous week, IGM Biosciences had 7 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 12 mentions for IGM Biosciences and 5 mentions for Aurinia Pharmaceuticals. IGM Biosciences' average media sentiment score of 0.57 beat Aurinia Pharmaceuticals' score of 0.41 indicating that IGM Biosciences is being referred to more favorably in the news media.
Aurinia Pharmaceuticals has a net margin of -32.69% compared to IGM Biosciences' net margin of -11,255.25%. Aurinia Pharmaceuticals' return on equity of -15.06% beat IGM Biosciences' return on equity.
Aurinia Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 85.87%. IGM Biosciences has a consensus target price of $17.89, suggesting a potential upside of 105.38%. Given IGM Biosciences' higher possible upside, analysts plainly believe IGM Biosciences is more favorable than Aurinia Pharmaceuticals.
36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 57.0% of IGM Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Aurinia Pharmaceuticals received 504 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 73.07% of users gave Aurinia Pharmaceuticals an outperform vote while only 48.84% of users gave IGM Biosciences an outperform vote.
Aurinia Pharmaceuticals has higher revenue and earnings than IGM Biosciences. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Aurinia Pharmaceuticals beats IGM Biosciences on 10 of the 18 factors compared between the two stocks.
Get Aurinia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurinia Pharmaceuticals Competitors List
Related Companies and Tools
